drug products covered by this notice that are marketed under an NDC number listed with the Agency in full compliance with section 510 of the FD&C Act before March 2, 2011. As previously stated, drug products covered by this notice that are currently marketed but not listed with the Agency on the date of this notice must, as of the effective date of this notice, have approved applications prior to their shipment in interstate commerce. Moreover, any person or firm that has submitted or submits an application but has yet to receive approval for such products is still responsible for full compliance with this notice.

V. Discontinued Products

Some firms may have previously discontinued the manufacturing or distribution of products covered by this notice without removing them from the listing of their products under section 510(j) of the FD&C Act. Other firms may discontinue manufacturing or marketing listed products in response to this notice. Firms that wish to notify the Agency of product discontinuation should send a letter, signed by the firm’s chief executive officer, fully identifying the discontinued product(s), including NDC number(s), and stating that the product(s) has (have) been discontinued. The letter should be sent to Sakineh Walther (see ADDRESSES). Firms should also update the listing of their products under section 510(j) of the FD&C Act to reflect discontinuation of products covered by this notice. FDA plans to rely on its existing records, including its drug listing records, or other available information when it targets violations for enforcement action.

This notice is issued under the Federal Food, Drug, and Cosmetic Act (sections 502 and 505 (21 U.S.C. 352 and 355)) and under authority delegated to the Assistant Commissioner for Policy under section 1410.21 of the FDA Staff Manual Guide.


Leslie Kux,
Acting Assistant Commissioner for Policy.

[FR Doc. 2011–4755 Filed 3–2–11; 8:45 am]

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### Health Resources and Services Administration

Advisory Committee on Organ Transplantation; Notice of Meeting

**AGENCY:** Health Resources and Services Administration, HHS.

**ACTION:** Notice; correction.

**SUMMARY:** The Health Resources and Services Administration published a notice in the Federal Register of February 9, 2011 (76 FR 7223–7224) announcing an Advisory Committee on Organ Transplantation meeting on March 8, 2011. The type of meeting, time and place have been changed.

**Correction**

In the Federal Register of February 9, 2011, in FR Doc. 2011–2839, on page 7223, 2nd column, under the heading Department of Health and Human Services, Health Resources and Services Administration, Advisory Committee on Organ Transplantation; Notice of Meeting, change the Times and Place to read:

The meeting will be an Audio Conference Call on March 8, 2011, from 12 noon to 4 p.m. EST. To access the conference call, call the USA Toll Free Number 888–469–1090 and enter the Passcode 2741198. The conference call leader is Patricia A. Stroup. Participants should call no later than 11:45 a.m. EST in order for logistics to be set up. Participants are asked to register for the conference call by contacting Brittany Carey, HRM/Professional and Scientific Associates (PSA), the logistical support contractor for the meeting, at (703) 889–9033 or b.carey@team-psa.com. The registration deadline is March 7, 2011. The Department will try to accommodate those wishing to participate in the call.

The next face-to-face ACOT meeting is planned for August 2011. Details regarding an August meeting will be published in a subsequent Federal Register notice.

Reva Harris,
Acting Director, Division of Policy and Information Coordination.

[FR Doc. 2011–4755 Filed 3–2–11; 8:45 am]
552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Center for Research Resources Special Emphasis Panel; Animal Models.
Date: March 15, 2011.
Time: 8 a.m. to 3 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Democracy I, 6701 Democracy Blvd., 1078, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Steven Birken, PhD, Scientific Review Officer, Office of Review, National Center for Research Resources, National Institutes of Health, 6701 Democracy Blvd., 10th Fl., Bethesda, MD 20892. (301) 435-1078, birken@nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: National Center for Research Resources Special Emphasis Panel; CTSA Coordinating Center.
Date: March 28, 2011.
Time: 1 p.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Democracy I, 6701 Democracy Blvd., 1064, Bethesda, MD 20892–4874 (Telephone Conference Call).
Contact Person: Guo Zhang, PhD, Scientific Review Officer, Office of Review, National Center for Research Resources, National Institutes of Health, 6701 Democracy Blvd., Dem. 1, Room 1064, MSC 4874, Bethesda, MD 20892–4874, 301–435–0812, zhanggu@mail.nih.gov.

(Digest of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research; 93.371, Biomedical Technology; 93.399, Research Infrastructure; 93.306, 93.333, 93.702, ARRA Related Construction Awards, National Institutes of Health, HHS)
Dated: February 25, 2011.

Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2011–4825 Filed 3–2–11; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Novel Drug Targets.
Date: March 23, 2011.
Time: 12:00 p.m. to 3 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6700B Rockledge Drive, 3147, Bethesda, MD 20817 (Telephone Conference Call).
Contact Person: Jane K. Battles, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institutes of Health/NIAID, 6700B Rockledge Drive, MSC 7616, Bethesda, MD 20892–7616, 301–451–2744, battlesja@mail.nih.gov.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Host-Pathogen Interactions.
Date: March 24, 2011.
Time: 12:30 p.m. to 4 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6700B Rockledge Drive, 3147, Bethesda, MD 20817 (Telephone Conference Call).
Contact Person: Jane K. Battles, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institutes of Health/NIAID, 6700B Rockledge Drive, MSC 7616, Bethesda, MD 20892–7616, 301–451–2744, battlesja@mail.nih.gov.

(Digest of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)
Dated: February 25, 2011.

Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2011–4823 Filed 3–2–11; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Consortia for AIDS Vaccine Research in Nonhuman Primates.
Date: March 29–30, 2011.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: Holiday Inn Georgetown, 2101 Wisconsin Avenue, NW., Washington, DC 20007.
Contact Person: Lynn Rust, PhD, Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institutes of Health/NIAID, 6700B Rockledge Drive, MSC 7616, Bethesda, MD 20892–7616, 301–496–2550.

(Digest of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)
Dated: February 25, 2011.

Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2011–4823 Filed 3–2–11; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Mental Health; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections

Dated: February 25, 2011.

Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2011–4824 Filed 3–2–11; 8:45 am]
BILLING CODE 4140–01–P